Introduction. Most acute myeloid leukemia (AML) patients with adverse prognosis either fail
to achieve complete remission (CR) or relapse after short-term remission, new strategies are …

Introduction: Acute myeloid leukemia (AML) is a life-threatening malignancy that primarily
afflicts an elderly population. Treatment of elderly patients with intensive chemotherapy is …

Abstract Background The hypomethylating agent Decitabine (DAC) is a valuable treatment
option in acute myeloid leukemia (AML), particularly in elderly patients (pts) not suitable for …

Background The DNA hypomethylating agents (HMAs) decitabine and azacitidine have
been widely used in the management of elderly patients with acute myeloid leukemia (AML) …

Standard chemotherapy is not curative for many patients with acute myeloid leukemia
(AML). New treatment strategies combining demethylating agents, such as decitabine, and …

Purpose This multicenter, randomized, open-label, phase III trial compared the efficacy and
safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute …

Background Many older patients with acute myeloid leukaemia die or cannot undergo
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …

Decitabine (DAC) is a well‐known DNA methyltransferase inhibitor, which has been widely
used for the treatment of acute myeloid leukemia (AML). However, in addition to …

Advances in DNA sequencing technologies have provided exceptional detail of the genomic
and epigenomic landscapes in acute myeloid leukemia (AML) 1, 2. A key insight emerging …

Background Relapsed/refractory (R/R) acute myeloid leukemia (AML) has poor outcomes.
Although lower‐intensity venetoclax‐containing regimens are standard for older/unfit …